ライフサイエンスコーパス: muscarinic

1 lar agonists unrelated either to 28 or known muscarinics.

2 We also reveal that D2-MSN LLP requires muscarinic 1 receptor activation, intracellular calcium

3 with IgGs against beta2-adrenergic receptor, muscarinic-2 receptors, AChR-nicotinic ganglionic alpha-

4 Previous work has shown that M(3) muscarinic acetylcholine (ACh) receptors (M3Rs) expresse

5 ABSTRACT: Gq -coupled M1-type muscarinic acetylcholine (ACh) receptors (mAChRs) mediat

6 Gq -coupled M1-type muscarinic acetylcholine (ACh) receptors (mAChRs) mediat

7 d adenosine 2B receptor and the G(q)-coupled muscarinic acetylcholine M1 receptor inhibited the activ

8 rs, including protease activated receptor 1, muscarinic acetylcholine M3, and histamine H1 receptors,

9 itive allosteric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (M1 mAChR) are a promi

10 sed biosensor to detect activation of the M1 muscarinic acetylcholine receptor (M1 mAChR) in vitro an

11 acetylcholine receptors, particularly the M1 muscarinic acetylcholine receptor (M1 mAChR), which was

12 The M2 muscarinic acetylcholine receptor (M2R) is a prototypica

13 The M2 muscarinic acetylcholine receptor (M2R) was found to exh

14 n and lung function regulated through the M3-muscarinic acetylcholine receptor (M3-mAChR).

15 levels of AuAbs to desmocollin 3 (Dsc3), M3 muscarinic acetylcholine receptor (M3AR), and secretory

16 (SMG), production of antinuclear and anti-M3 muscarinic acetylcholine receptor (M3R) autoantibodies a

17 itive allosteric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (mAChR) achieve exquis

18 ation of vestibular afferents is mediated by muscarinic acetylcholine receptor (mAChR) activation and

19 Muscarinic acetylcholine receptor (mAChR) activation in

20 Nanoinjections of the muscarinic acetylcholine receptor (mAChR) agonist, oxotr

21 series of novel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 w

22 Muscarinic acetylcholine receptor (mAChR) blockade by sc

23 pe-selective allosteric modulators of the M5 muscarinic acetylcholine receptor (mAChR) have been desc

24 t deficits in signaling of the M1 subtype of muscarinic acetylcholine receptor (mAChR) in the prefron

25 The M(1) muscarinic acetylcholine receptor (mAChR) plays an impor

26 M(1) muscarinic acetylcholine receptor (mAChR) positive allos

27 Selective activation of the M1 muscarinic acetylcholine receptor (mAChR) via a positive

28 We previously reported a form of muscarinic acetylcholine receptor (mAChR)-dependent long

29 Genetic studies further indicate that muscarinic acetylcholine receptor (mAchR)/Galphao signal

30 luorescently labeled dibenzodiazepinone-type muscarinic acetylcholine receptor (MR) antagonists, incl

31 while enhancing myelination by deleting the muscarinic acetylcholine receptor 1 in oligodendrocyte p

32 , we find that the Chrm4 transcript encoding muscarinic acetylcholine receptor 4 (M4) is excessively

33 We and others have investigated muscarinic acetylcholine receptor 4 (M4) positive allost

34 both pharmacologic blockade of M-current and muscarinic acetylcholine receptor activation.

35 ble toolbox derivatives of the highly potent muscarinic acetylcholine receptor agonist iperoxo.

36 Scopolamine (hyoscine) is a muscarinic acetylcholine receptor antagonist that has tr

37 demonstrate that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces r

38 ve revealed that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces r

39 mine (NMS) bind to the binding pocket of the muscarinic acetylcholine receptor formed by transmembran

40 ric modulators (PAMs) of the M(1) subtype of muscarinic acetylcholine receptor have emerged as an exc

41 uggest that selective activators of the M(4) muscarinic acetylcholine receptor have potential as a no

42 The muscarinic acetylcholine receptor is an important modula

43 e prospectively apply our model to the human muscarinic acetylcholine receptor M1, finding four exper

44 typically express somatostatin, VIP, or the muscarinic acetylcholine receptor M2.

45 Human acini preferentially expressed the muscarinic acetylcholine receptor M3 and maintained phys

46 ed inflammatory cytokines and decreased M3R (Muscarinic Acetylcholine receptor M3) and AQP5 (Aquapori

47 ubstantia nigra pars reticulata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M4) to oppo

48 Mice with targeted disruption of single muscarinic acetylcholine receptor subtype genes (M(1) to

49 the PET radiotracer (11)C-LSN3172176 for the muscarinic acetylcholine receptor subtype M1.

50 gG reactivity in patients with PV toward the muscarinic acetylcholine receptor subtypes 3, 4, and 5 a

51 enous actuator ligand to activate a modified muscarinic acetylcholine receptor that is insensitive to

52 imary and secondary Gi/o coupling, using the muscarinic acetylcholine receptor type 2 (M2R) as the pr

53 through an acetylcholine-gated channel and a muscarinic acetylcholine receptor, respectively.

54 g pattern of geniculocortical inputs with M2 muscarinic acetylcholine receptor-rich patches in layer

55 beta2 adrenergic receptor (hbeta2AR) and M2 muscarinic acetylcholine receptor.

56 an be recapitulated with blockade of M1-type muscarinic acetylcholine receptors (M1-AChR); however, t

57 consistent with beta-arrestin binding to M1 muscarinic acetylcholine receptors (M1Rs) in two differe

58 Muscarinic acetylcholine receptors (mAChR) play importan

59 tory learning in adult flies requires type A muscarinic acetylcholine receptors (mAChR-A), particular

60 duced by mamba snakes that primarily bind to muscarinic acetylcholine receptors (MAChRs) and modulate

61 Furthermore, inhibition of muscarinic acetylcholine receptors (mAChRs) reduced calc

62 We also characterized two types (A and B) of muscarinic acetylcholine receptors (mAChRs), which were

63 Muscarinic acetylcholine receptors (MRs), comprising fiv

64 ces, we show that endogenous Galphaq-coupled muscarinic acetylcholine receptors activate PKA.

65 Muscarinic acetylcholine receptors are G protein-coupled

66 Muscarinic acetylcholine receptors are G-protein-coupled

67 M1 muscarinic acetylcholine receptors are highly expressed

68 Muscarinic acetylcholine receptors have been implicated

69 is known about the physiological function of muscarinic acetylcholine receptors in learning in adult

70 This strongly suggests a role of muscarinic acetylcholine receptors in the generalized se

71 The drug scopolamine was used to block muscarinic acetylcholine receptors involved in working m

72 We assessed the contribution of muscarinic acetylcholine receptors to motivated behaviou

73 CIN firing by CRF results in the activation muscarinic acetylcholine receptors type 5, which mediate

74 ere agonist binding follows hyperbolic (M(4) muscarinic acetylcholine receptors) or nonhyperbolic rel

75 her syndrome was due to autoimmunity against muscarinic acetylcholine receptors, blocking their activ

76 lternative strategy is to selectively target muscarinic acetylcholine receptors, particularly the M1

77 diolabeled species from all five subtypes of muscarinic acetylcholine receptors, suggesting allosteri

78 macotherapy with nonselective antagonists of muscarinic acetylcholine receptors, which have many unde

79 HVC activity and was attenuated by blocking muscarinic acetylcholine receptors.

80 phenotype can be rescued by an antagonist of muscarinic acetylcholine receptors.

81 ergic G protein-coupled receptors, including muscarinic acetylcholine receptors.

82 y acetylcholine acting on both nicotinic and muscarinic acetylcholine receptors.

83 No difference in muscarinic acetylcholine type 2 receptor expression was

84 alpha-7 nicotinic acetylcholine receptor and muscarinic acetylcholine type 2 receptor expression, as

85 inic acetylcholine receptor) and muscarinic (muscarinic acetylcholine type 2 receptor) receptors, and

86 tropine, indicating that it requires ACh and muscarinic ACh receptor (mAChR) activation.

87 (nAChR)-mediated depolarizing potentials and muscarinic ACh receptor (mAChR)-mediated hyperpolarizing

88 ntiated whisker-evoked CBF responses through muscarinic ACh receptors and concurrently facilitated ne

89 Sensory neurons from mice lacking the muscarinic ACh type 1 receptor (M1R) exhibited enhanced

90 While the muscarinic ACh-receptors M3R and M1R are activating, M2R

91 marker for future clinical investigations of muscarinic agents, and bear mechanistic relevance for th

92 Acinar cell responses to the muscarinic agonist carbachol (CCh) and the bile acid tau

93 lastoma cells, activation of ADAM10 with the muscarinic agonist carbachol promotes PrP(C) shedding an

94 al rat ventricular myocytes treated with the muscarinic agonist carbachol.

95 tion upon pharmacological treatment with the muscarinic agonist carbachol.

96 viorally active dose of the M1/M4-preferring muscarinic agonist xanomeline on brain functional activi

97 nd is classified as either a full or partial muscarinic agonist.

98 timulating mouse-eye pupil constriction than muscarinic agonists oxotremorin-M (Oxo-M) or carbachol (

99 brain-wide functional substrates engaged by muscarinic agonists remain poorly understood.

100 s to treat airway disease include the use of muscarinic and leukotriene receptor antagonists; however

101 Muscarinic and nicotinic cholinergic receptors both cont

102 Cluster analysis revealed that muscarinic and nicotinic effects on attentional control

103 arbamylcholine on VFT that depends upon both muscarinic and nicotinic receptor stimulation, where the

104 effect of CCh on VFT that depends upon both muscarinic and nicotinic receptor stimulation, where the

105 Here we delineate how muscarinic and nicotinic receptors affect basic neuronal

106 piking and narrow spiking cells both require muscarinic and nicotinic receptors for normal excitabili

107 identified roles for both acetylcholinergic muscarinic and nicotinic receptors in different mood sta

108 d spiking cells, while they depended on both muscarinic and nicotinic receptors in narrow spiking cel

109 ng and flow cytometry, and the expression of muscarinic and nicotinic receptors was evaluated by flow

110 l and combined pharmacological inhibition of muscarinic and/or beta-adrenergic receptors.

111 ice were treated with i-Extract, followed by muscarinic antagonist (dicyclomine) and agonist (pilocar

112 s an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatme

113 ng-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LA

114 Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as triple therapy

115 agonist [LTRA], theophylline, or long-acting muscarinic antagonist [LAMA]) steadily increased over ti

116 ntagonists would worsen pathophysiology, the muscarinic antagonist atropine reduced IIS frequency.

117 rsus a long-acting beta2-agonist/long-acting muscarinic antagonist combination for exacerbation preve

118 Finally, we designed a muscarinic antagonist DART in one iteration, demonstrati

119 -daily long-acting beta2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50

120 selective GluN2B antagonist, CP-101,606 and muscarinic antagonist scopolamine which have both been s

121 (ICS) (n = 1097), 5 RCTs of the long-acting muscarinic antagonist tiotropium (n = 4592), and 6 RCTs

122 controlled asthma, addition of a long-acting muscarinic antagonist to inhaled corticosteroid plus lon

123 agonist), and glycopyrronium (G; long-acting muscarinic antagonist) with the combination of BDP with

124 d glucocorticoid), tiotropium (a long-acting muscarinic antagonist), or placebo.

125 er controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and biological

126 -adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reduction

127 Add-on long-acting muscarinic antagonists are recommended in individuals wh

128 There is concern that long-acting muscarinic antagonists increase cardiovascular morbidity

129 e odds ratio for prescription of long-acting muscarinic antagonists was 2.27 (95% CI = 1.38-3.70).

130 ong-acting beta(2)-agonists plus long-acting muscarinic antagonists) or triple inhaled therapy (inhal

131 ong-acting beta(2)-agonists plus long-acting muscarinic antagonists).

132 They were prevented by the M1-preferring muscarinic antagonists, telenzepine, pirenzepine, and tr

133 sal with acetylcholinesterase inhibitors and muscarinic anticholinergics in these patients.

134 The effect of CCh on VFT was abolished by a muscarinic (atropine, 0.1 mumol l(-1) , n = 6) or a nico

135 Although the combination of muscarinic-based DREADDs with clozapine-N-oxide (CNO) ha

136 lective agonist deschloroclozapine (DCZ) for muscarinic-based DREADDs.

137 ory stimulation by activating a long-lasting muscarinic cation current in motoneurons.

138 n of GABA agonists was mimicked by intra-LHb muscarinic cholinergic (mACh) antagonist injection, and

139 t diminished insulin secretion evoked by the muscarinic cholinergic agonist Oxo-M.

140 Injection of muscarinic cholinergic antagonists, scopolamine methyl b

141 While muscarinic cholinergic blockade prevented the VNS-induce

142 KEY POINTS: A tonically active, muscarinic cholinergic inhibition of rostral raphe palli

143 The RVLM is not the sole source of the muscarinic cholinergic input to rRPa.

144 Importantly, we document increased muscarinic cholinergic receptor expression in Alexander

145 In pancreatic beta cells, muscarinic cholinergic receptor M3 (M3R) stimulates gluc

146 anule cell layer, express both nicotinic and muscarinic cholinergic receptors.

147 d natural compounds, and found that reducing muscarinic cholinergic signaling ameliorated clinical sy

148 its, glycopyrrolate, we confirm the role for muscarinic cholinergic signaling in pathogenesis using a

149 We further demonstrate that muscarinic cholinergic signaling works through downstrea

150 ng systemic administration of scopolamine, a muscarinic-cholinergic receptor antagonist.

151 early intervention with cholinergic receptor muscarinic (ChRM)-3 blocker reversed the progression of

152 hic pain rats due to a severe reduction of a muscarinic depolarizing current and M1 receptor internal

153 pounds, but not cannabinoid, neurotensin, or muscarinic drugs.

154 k-in mutation T853A in mice had no effect on muscarinic force responses in isolated tracheal tissues.

155 by designer drugs) system in which a mutated muscarinic G protein-coupled receptor is activated by an

156 blation or pharmacological inhibition of the muscarinic-gated K(+) channel (IKACh) could rescue SSS a

157 to investigate structural dynamics of the M2 muscarinic GPCR that is bound by the full agonist iperox

158 functions through its actions on epithelial muscarinic Gq-coupled receptors such as M3R.

159 G-RyR2 Ser-2808 signaling and independent of muscarinic-induced phosphorylation of Ser-239 in vasodil

160 These results provide detailed insights into muscarinic-induced PKG signaling and the mediators that

161 nfirming the existence of a tonic inhibitory muscarinic influence on cardiac inotropy.

162 confirm the existence of a tonic inhibitory muscarinic influence on LV contractility.

163 ted cation (I (h) ), slow-inactivating K(+), muscarinic K(+), and Ca(2+) L-type.

164 mpus of mice following administration of the muscarinic ligands xanomeline and 1-(4-methoxybenzyl)-4-

165 amidal cells, the effects of G(q/11)-coupled muscarinic M(1) acetylcholine (M(1)R) stimulation on M c

166 but also the pharmacological profile at the muscarinic M(1) receptor.

167 (2), serotonin 5-HT(2A), histamine H(1), and muscarinic M(1) receptors, and favorable druglike proper

168 Muscarinic M(3) receptor antagonists and inverse agonist

169 receptors, without showing an alteration of muscarinic M(3) receptors.

170 Here, we examined signaling evoked by muscarinic (M(2)R) and adenosine (A(1)R) receptor activa

171 ic AMPA, NMDA and kainate, GABAergic GABAA , muscarinic M1 , M2 and nicotinic acetylcholine (nACh; al

172 istamine H1 and H2, melanocortin, melatonin, muscarinic M1 and M3, neurokinin, opioid KOP and seroton

173 Stimulation of the cortical muscarinic M1 receptor (CHRM1) is proposed as a treatmen

174 ent data demonstrated that activation of the muscarinic M1 receptor by a subtype-selective positive a

175 s expressing some 50 molecules.mum(-2) human muscarinic M1 receptor identified a approximately 75:25

176 This study investigated the role of muscarinic M1 receptors (M1Rs) in the dlPFC using iontop

177 M8 by activation of heterologously expressed muscarinic M1 receptors.

178 Muscarinic M1-M5 acetylcholine receptors are G-protein-c

179 t phases of the cue detection process, while muscarinic (M1) receptor activity was preferentially inv

180 t of spontaneous receptor activity using the muscarinic M2 acetylcholine receptor as a model.

181 compounds that elicit protean agonism at the muscarinic M2 acetylcholine receptor.

182 of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explo

183 Muscarinic m2 receptors (M2Rs) are implicated in autoreg

184 ect on the QT interval, and its affinity for muscarinic M2 receptors resulted in transient heart rate

185 ic/allosteric (i.e. dualsteric) agonists for muscarinic M2 receptors to demonstrate the existence and

186 and tightly controlled by autoinhibition via muscarinic M2 receptors.

187 d results pertaining to its interaction with muscarinic M3 receptor (M3R).

188 mediated through the Gs-coupled modified rat muscarinic M3 receptor (rM3Ds) induced appreciable dyski

189 ignaling Gbeta5-R7 is a crucial activator of muscarinic M3 receptor-stimulated insulin secretion.

190 ctivated receptors, heterologously expressed muscarinic M3 receptors, or by direct activation of inos

191 ivation of a G-protein-coupled receptor, the muscarinic M5R, results in DAT-mediated DA efflux throug

192 ly affects HMNs by a variable combination of muscarinic-mediated excitatory and inhibitory responses.

193 This was enhanced by muscarinic-mediated PtdIns(4,5)P(2) hydrolysis, leading

194 sms underlying the antipsychotic efficacy of muscarinic modulators are not well understood.

195 lpha-7 nicotinic acetylcholine receptor) and muscarinic (muscarinic acetylcholine type 2 receptor) re

196 r this was dependent on NO generation and/or muscarinic/nicotinic receptor stimulation.

197 Attentional control signals depended on muscarinic, not nicotinic receptors in broad spiking cel

198 on Src activity, betaarr1 in complex with M2 muscarinic or beta2-adrenergic receptors reconstituted i

199 excellent model for testing the efficacy of muscarinic pharmacological entities.

200 my, 4) nicotinic receptor (mecamylamine) and muscarinic receptor (AQ-RA 741) blockade, and 5) ex vivo

201 lidal MSN activity via a Gq-coupled human M3 muscarinic receptor (hM3Dq), a type of designer receptor

202 Using the activatory Gq-coupled human M3 muscarinic receptor (hM3Dq), we found that chemogenetic

203 ized the oligomeric status of eGFP-tagged M2 muscarinic receptor (M2R) and Gi1 by single-particle pho

204 -2 regulates expression of the C. elegans M2 muscarinic receptor (m2R) ortholog, GAR-2.

205 eta-arrestin 1 (betaarr1) in complex with M2 muscarinic receptor (M2R) reconstituted in lipid nanodis

206 eceptor that activates KACh channels, the M2 muscarinic receptor (M2R).

207 l subunits [Cacna1c and Cacnb2], cholinergic muscarinic receptor 4 [Chrm4)], dopamine receptor D2 [Dr

208 omponents of the signalling pathway coupling muscarinic receptor activation to changes in chemorecept

209 Moreover, muscarinic receptor activation, and in particular M2 sub

210 obust and more sustained increase induced by muscarinic receptor activation.

211 y TRPV1 activation but not that evoked by M1 muscarinic receptor activation.

212 d theta oscillations, and both nicotinic and muscarinic receptor activity contributed to this process

213 RTN chemoreceptors to ACh was mimicked by a muscarinic receptor agonist (oxotremorine; 1 mum), and b

214 orylation of Ser-2808 in RyR2 induced by the muscarinic receptor agonist carbachol is mediated by a s

215 that SPARC enhanced the promoting effect of Muscarinic receptor agonist oxotremorine-M on insulin se

216 served more than 30 min after removal of the muscarinic receptor agonist.

217 Muscarinic receptor agonists are characterized by appare

218 currently limited to medications (e.g., the muscarinic receptor agonists pilocarpine and cevimeline)

219 Here, we find that nonselective muscarinic receptor antagonism in mice as well as epithe

220 formance was facilitated by the nonselective muscarinic receptor antagonist scopolamine as well as th

221 ent and the ratio of those using long-acting muscarinic receptor antagonist were higher than those in

222 Here, we show that the muscarinic receptor antagonist, atropine, eliminated the

223 of scopolamine, a nonselective acetylcholine muscarinic receptor antagonist.

224 of long-acting beta(2) agonists/long-acting muscarinic receptor antagonists as the preferred treatme

225 rendered ineffective by either nicotinic or muscarinic receptor antagonists.

226 Our study identified muscarinic receptor as a key target of i-Extract, provid

227 The M2 muscarinic receptor is the prototypic model of allostery

228 tussis toxin or in myocytes from M2- or M1/3-muscarinic receptor knockout mice, atropine increased cA

229 beta(2)-adrenergic and M(2)-muscarinic receptor mRNA and beta(2)-receptor protein we

230 We performed muscarinic receptor radioligand binding.

231 y and underlie the K(+) current sensitive to muscarinic receptor signaling (the M current) in sympath

232 ted the hypothesis that the lack of a single muscarinic receptor subtype leads to age-dependent neuro

233 There are five muscarinic receptor subtypes (M1R to M5R), which, despit

234 n's Syndrome (SS) and HCV, presence of anti- muscarinic receptor type 3 (M3R) antibodies in SS, the r

235 Here we show that muscarinic receptor type-1 (Chrm1) signaling in the hypo

236 M2 immunoreactivity and M3 mRNA levels of muscarinic receptor were increased at day 7.

237 orded with another cognate G protein-coupled muscarinic receptor, M1R.

238 ium-dependent vasodilatations in response to muscarinic receptor, TRPV4 (transient receptor potential

239 al proliferation and tumorigenesis in an ACh muscarinic receptor-3 (M3R)-dependent manner, in part th

240 t study, by expressing an arrestin-biased M3 muscarinic receptor-based DREADD (M3D-arr) in stable hER

241 orylation site in a region homologous to the muscarinic receptor-binding site of Tau suggests that MA

242 r cholinergic constraint that is mediated by muscarinic receptor-dependent regulation of mitochondria

243 This occurs in part via transient-evoked muscarinic receptor-mediated high-frequency oscillations

244 modulation of signals transduced by the M(3) muscarinic receptor/G(q)/PLCbeta pathway at the plasma m

245 ayers of primary motor cortex (M1) through a muscarinic-receptor mediated mechanism, gamma oscillatio

246 enzyme-linked immunosorbent assay for all 5 muscarinic receptors (M(1) -M(5) ), we identified in the

247 Activation of M2 muscarinic receptors (M2Rs) in the rat anterior basolate

248 Indeed, muscarinic receptors (mAChRs) regulate the repair phenot

249 adoxical excitation was caused by overactive muscarinic receptors (mAChRs), leading to a switch in D2

250 electivity, has been increasingly applied to muscarinic receptors (MRs).

251 neurotransmitter acetylcholine, we show that muscarinic receptors 1 and 3 (m1 and m3) are highly expr

252 to the efficient coupling between endogenous muscarinic receptors and GIRK channels, we found that fi

253 garding the intrinsic voltage sensitivity of muscarinic receptors and the consequences of this intrig

254 port the crystal structures of the M1 and M4 muscarinic receptors bound to the inverse agonist, tiotr

255 e et al. (2017) demonstrate that presynaptic muscarinic receptors counteract the effects of dopamine

256 The procedure was verified at M(2) and M(4) muscarinic receptors fused with the G(15) G-protein alph

257 Blockade of muscarinic receptors had no effect on evoked dopamine re

258 Cholinergic drugs acting at M1/M4 muscarinic receptors hold promise for the treatment of s

259 lexander disease patients, and that blocking muscarinic receptors in Alexander disease model mice red

260 The finding that blockade of muscarinic receptors in mPFC impaired trace conditioning

261 x behavior of oligomers is characteristic of muscarinic receptors in myocardial preparations.

262 These results indicate that muscarinic receptors in striatal output neurons reliably

263 output under control conditions but not when muscarinic receptors in the RTN are blocked.

264 e-dependent inhibition of DA release through muscarinic receptors only in the shell, where higher act

265 M1 muscarinic receptors regulate the phosphorylation of AMP

266 Muscarinic receptors represent a promising therapeutic t

267 this notion, we find that sAHP inhibition by muscarinic receptors that increase phosphoinositide turn

268 tylcholine release at these synapses allowed muscarinic receptors to faithfully encode physiological

269 nges, which involved the mechanisms of BDNF, muscarinic receptors, and beta3-adrenoceptor expression.

270 usly shown that dendritic cells (DC) express muscarinic receptors, as well as the enzymes responsible

271 lycemia was abolished by blocking peripheral muscarinic receptors, consistent with the hypothesis tha

272 ACh, via M2 muscarinic receptors, contributes to the modulation and

273 We also evaluate the ability of muscarinic receptors, in particular the M2 subtype, to m

274 which is a known allosteric modulator of the muscarinic receptors, is also shown to be a modulator of

275 cal blockade of nicotinic receptors, but not muscarinic receptors, prevented heart block and mortalit

276 sal striatum and pharmacological blockade of muscarinic receptors, specifically postsynaptic M1 and M

277 rough distinct actions at both nicotinic and muscarinic receptors, triggers a procession of neural os

278 vasodilatations in response to activation of muscarinic receptors, TRPV4 channels or IK/SK channels w

279 By focusing on muscarinic receptors, which are activated by the nerve-d

280 neurons through presynaptic and postsynaptic muscarinic receptors.

281 uately explained solely by its antagonism at muscarinic receptors.

282 parasympathetic ACh slows the heart through muscarinic receptors.

283 t some neurons in nP, TS, and tectum express muscarinic receptors.

284 e from mossy fibers by acting on presynaptic muscarinic receptors.

285 d RGS4, a negative regulator of beta-cell M3 muscarinic receptors.

286 Thus, nerve-mediated muscarinic responses in signalling modules acting on RLC

287 defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based

288 ations were consistent with suppression of a muscarinic-sensitive K(+)-current, or M-current.

289 provide novel therapeutic opportunities for muscarinic-signal-driven CRPC progression by targeting t

290 We have therefore identified glial muscarinic signaling as a potential therapeutic target i

291 ck-out mice experiments demonstrated that M1 muscarinic signaling is critical for cholinergic control

292 The fact that we also show that muscarinic signaling is maintained in both AD and mouse

293 Thus, enhancing hippocampal muscarinic signaling using M1 mAChR PAMs restored memory

294 itide metabolism in sympathetic neurons upon muscarinic stimulation and used the kinetic information

295 nositol 1,4,5-trisphosphate, and Ca(2+) upon muscarinic stimulation in sympathetic neurons from adult

296 ve illuminated previously unknown actions of muscarinic stimulation on the excitability of hippocampa

297 tdIns(4,5)P(2) recovery following repetitive muscarinic stimulation, with no apparent impact on resti

298 othesize that i-Extract may primarily target muscarinic subtype acetylcholine receptors that regulate

299 tive antagonists, pirenzepine, VU0255035, or muscarinic toxin 7 (MT7) activated AMPK and overcame dia

300 Muscarinic toxins (MTs) are natural toxins produced by m

301 Expression of muscarinic type 2, 3 (M(2) , M(3) ), and NK(1) receptors